NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots
Executive Summary
The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.
You may also be interested in...
FDA, NIH Devise Regulatory Research Agenda, Look For Financing
The budget sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin notes. The Institute of Medicine recommends more collaborations to strengthen the Clinical and Translational Science Awards program.
FDA, NIH Devise Regulatory Research Agenda, Look For Financing
The budget sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin notes. The Institute of Medicine recommends more collaborations to strengthen the Clinical and Translational Science Awards program.
FDA, NIH Devise Regulatory Research Agenda, Look For Financing
The sequester is making it difficult to fund new projects, “no matter how high a priority,” National Center for Advancing Translational Sciences Director Christopher Austin noted during a June 25 teleconference to discuss Institute of Medicine recommendations for strengthening the Clinical and Translational Science Awards program.